IL-6401-일동제약-CysGvHD-null-solid tumors

IL-6401 is a drug candidate listed in the pipeline of Ildong Pharmaceutical. Based on available pipeline data, it is being investigated for the treatment of solid tumors. However, the specific mechanism of action and biological target for this code name are not clearly defined in public records, and the entry appears to be a garbled extraction from a pipeline table where the target was listed as 'CysGvHD' and the modality as 'null'. These values are likely errors resulting from OCR or data extraction processes from the original source. Given the context of Ildong's oncology pipeline, it may represent a misidentified project or a specific early-stage candidate developed in collaboration with partners such as I-Mab Biopharma or Yurogen Biosystems.